Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms-Reference-Cited by-同舟云学术

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms

Published:2007-01 Issue:1 Volume:120 Page:72-82.e3
ISSN:0002-9343
Container-title:The American Journal of Medicine
language:en
Short-container-title:The American Journal of Medicine

Author:

Hull Russell D.,Pineo Graham F.,Brant Rollin F.,Mah Andrew F.,Burke Natasha,Dear Richard,Wong Turnly,Cook Roy,Solymoss Susan,Poon Man-Chiu,Raskob Gary

Publisher

Elsevier BV

Subject

General Medicine

Reference50 articles.

1. Antithrombotic therapy for venous thromboembolic disease;Hyers;Chest,2001

2. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis;Levine;N Engl J Med,1996

3. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home;Koopman;N Engl J Med,1996

4. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis;Hull;N Engl J Med,1982

5. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range;Hirsh;Chest,2001

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis;Cancers;2023-09-20

2. Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism;Current Oncology Reports;2023-06-06

3. Bleeding Risk in Elderly Patients with Venous Thromboembolism Who Would Have Been Excluded from Anticoagulation Trials;Thrombosis and Haemostasis;2023-01-09

4. Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review;International Journal of Clinical Practice;2022-07-19

5. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants;Thrombosis and Haemostasis;2020-06